Airway microbiota correlated with pulmonary exacerbation in primary ciliary dyskinesia patients

Microbiol Spectr. 2023 Dec 12;11(6):e0221323. doi: 10.1128/spectrum.02213-23. Epub 2023 Oct 5.

Abstract

PCD is a rare disease characterized by productive cough, rhinitis, and recurrent infections of the upper and lower airways. Because the diagnosis of PCD is often delayed, patients receive more antibiotics, experience a heavier financial burden, and have a worse prognosis; thus, it is very important to identify the pathogeny and use the correct antibiotic. In this large single-center study of PCD microbiota, we identified an outline of the bacterial microbes from the respiratory tract; furthermore, we found that the microbiota diversity in pediatric sputum was richer than that in pediatric BALF through sequencing, indicating a heterogeneous community structure. The microbiota diversity and richness were lower during pulmonary exacerbation than during pulmonary stabilization. A significantly higher abundance of Pseudomonas had a moderate distinguishing effect for lung exacerbation, which attracted more attention for the study of Pseudomonas therapy in pediatric patients with PCD.

Keywords: airway microbiota; microbiota diversity; primary ciliary dyskinesia; pulmonary exacerbation.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Humans
  • Kartagener Syndrome* / diagnosis
  • Kartagener Syndrome* / drug therapy
  • Lung
  • Microbiota*
  • Sputum / microbiology

Substances

  • Anti-Bacterial Agents